Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch V: State-of-the-art smartphone with healthcare capabilities empowering patients and consumers (with document)

Un document

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
New Products/LifeWatch V Smart Phone

27.06.2012

Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless cardiac monitoring service and home sleep test provider in
the U.S., presents today LifeWatch V, the world's first-of-its-kind healthcare
smartphone. The fully featured state-of-the-art smartphone allows patients as
well as health- and wellbeing-conscious consumers to self-operate a wide range
of highly valuable embedded medical sensors, wellness-related applications,
cloud-based services and 24/7 call center support.

You will find a PDF-Version of this press release at the end of this message.

As a next step of its product and geographical diversification LifeWatch
presents today LifeWatch V, the world's first fully featured smartphone which
operates on an android OS. The state-of-the-art solution offers multiple
sophisticated embedded medical miniature sensors, wellness-related
applications, cloud-based services and 24/7 call center support. By using the
barely visible sensors on the phone's frame, patients as well as health- and
wellbeing conscious consumers can track, capture, collect and analyze their
health and medical measurements anywhere anytime. The features include ECG,
body temperature, blood glucose, heart rate, blood oxygen saturation, body fat
percentage and stress levels (heart rate variability). All collected data can
be retrieved from the cloud for a follow-up anytime anywhere. Users can thus
take corrective action, plan their diets and activities, securely share the
information with a health provider or family member, trend and analyze the data
and more. Patients are also able to program the unit to remind them of their
drug type, dose and intake time.

LifeWatch V with add-on service offering:

LifeWatch V was designed with a flexible service-product ecosystem in mind,
allowing easy integration of services. The LifeWatch V handset unit includes a
service enablement platform to support the transmission of medical data to be
analyzed, evaluated and communicated to health professionals and call center
personnel around the clock. The device wirelessly interacts with a cloud-based
environment allowing users direct access to a wide range of valuable
complementary medical and wellness related services.


Strategic alliances with local partners:

Smartphones are positioned to overtake many computing functions that were
reserved to computers alone. More importantly, the smartphone has emerged as an
intimate device consumers carry with them anywhere and anytime, making it an
ideal vehicle to let users self-test their health, especially users with an
interest in the medical field. Recent market developments have witnessed the
emergence of health-dedicated cellular phones.

Based on a full and complete Go-to-Market analysis LifeWatch intends to launch
the healthcare solution smartphone world-wide. In the initial markets LifeWatch
has identified several local partners to enter into strategic partnerships.




|LifeWatch V: Medical specifications                                           
|
|EKG (1-Lead)                 |EKG dynamic range 0.15-5 mV.                    
|
|                             |Frequency response 0.5-40 Hz.                   
|
|                             |Sampling 12 bit, 250 samples /sec.              
|
|                             |Test time: Average of 35 sec.                   
|
|Heart rate                   |HF measurement range 30 to 250 bpm              
|
|                             |QRS detection sensitivity > 98%                 
|
|                             |QRS detection  predictability > 98%             
|
|                             |Result time: Average of 10 sec.                 
|
|SpO2                         |Method: Reflective R & IR emission              
|
|                             |Oxygen saturation range: 70 to 100%             
|
|                             |Accuracy: Standard deviation ± 1 digits         
|
|                             |Test time: Average of 20 sec.                   
|
|Glucose                      |Range: 10-650 mg/dl                             
|
|                             |Sample size: 0,4-0,7 ?L                         
|
|                             |Accuracy: ± 10 mg/dL for glucose level < 75
mg/dL|
|                             |                                                
|
|                             |12.5% for glucose level => 75 mg/dL             
|
|                             |Test time: 3-5 sec.                             
|
|IR-Thermometer               |Range: 34 to 41 C°; Accuracy: ± 0,2 C°          
|
|Body fat percentage          |Method: Bioelectrical Impedance                 
|
|Operating temperature        |10 to 40 C° (40 to 104 °F)                      
|


LifeWatch V: Technical specifications                                          |
|Network                      |3G 850/1900/2100; 2G 850/900/1800/1900; 3G      
|
|                             |(HSDPA, 7.2 Mbps)                               
|
|Operating system             |Android 2.3 (Gingerbread)                       
|
|Processor                    |Qualcomm MSM7227Turbo                           
|
|Weight and dimensions (HxWxD)|162g; 132(mm) x 70.8(mm) x 13.2(mm)             
|
|Display                      |LCD 4.3" 480*480 Pixels (WVGA)                  
|
|Battery capacity-            |1500 mAh                                        
|
|Camera                       |5MP main camera + 300KP front camera            
|
|Connectivity                 |Bluetooth Ver. 2.1 with BT/Wi-Fi-coexistence    
|
|                             |Wi-Fi IEEE 802.11b/g/n                          
|
|Memory                       |1GB Flash, 512MB RAM, T-Flash, Micro SD Slot (up
|
|                             |to 32GB)                                        
|
|Certification                |CE- Mark pending                                
|
|Features                     |GPS, A-GPS supported                            
|


Don't miss it: Join us for a live presentation of LifeWatch V today:

Live demonstration: June 27, 2012, 3:30 p.m., Zurich, Metropol,
Fraumünsterstrasse 12;

Live Video Webcast in the IR section on www.lifewatch.com
Product website: http://www.lifewatchv.com/demo/


About LifeWatch AG:
 
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote
patient monitoring services. LifeWatch services cater to individuals, ranging

from high-risk and chronically ill patients, to consumers of health and
wellness products. LifeWatch has subsidiaries in the United States, the
Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is
the parent company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology products.
LifeWatch is also introducing a new program for Home Sleep Testing of
Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For
additional information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are forward-
looking statements. The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended to
identify forward-looking statements. LifeWatch AG has based these forward-
looking statements largely on current expectations and projections about future
events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the forward-
looking statements. All forward-looking statements are based only on data
available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/19lpaarY

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12 | Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/19lpaarY


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
             SIX Swiss Exchange 
language:   English

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG